🔎 Trials Near Me

Home › Major Depressive Disorder › New York

Major Depressive Disorder clinical trials in New York

48 studies for Major Depressive Disorder are looking for participants at sites in New York.

Cities in New York

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  • Adams Clinical Bronx, The Bronx
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  • Integrative Clinical Trials LLC, Brooklyn
  • SPRI Clinical Trials, LLC, Brooklyn
  • Bioscience Research LLC, Mount Kisco
  • and 3 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Oct 1, 2026 · NCT07573176

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  • Integrative Clinical Trials LLC, Brooklyn
  • SPRI Clinical Trials, LLC, Brooklyn
  • Bioscience Research LLC, Mount Kisco
  • and 1 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

  • Ima Clinical Research - Nyc Midtown, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  • SPRI Clinical Trials, LLC, Brooklyn
  • Manhattan Behavioral Medicine, New York
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  • Adams Clinical Harlem, New York
  • New York State Psychiatric Institute, New York
  • Davis Clinical (Adams Clinical Bronx), The Bronx
  • and 1 more
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  • Vanda Investigational Site, New York
  • Vanda Investigational Site, New York
  • Vanda Investigational Site, Staten Island
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044

DBS for TRD With the Medtronic Percept PC

  • Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York
Recruiting
Ages 25 to 70 · All sexes · Updated Sep 22, 2026 · NCT05773755

Pattern Separation in Major Depressive Disorder

  • New York State Psychiatric Institute (NYSPI), New York
RecruitingPhase 1
Ages 18 to 50 · All sexes · Updated Sep 15, 2026 · NCT07139834

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  • Seaport Investigator Site, Brooklyn
  • Seaport Investigator Site, Cedarhurst
  • Seaport Investigator Site, New York
  • and 1 more
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07065240

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

  • Integrative Clinical Trials LLC, Brooklyn
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07284667

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  • Bioscience Research, LLC, Mount Kisco
  • Fieve Clinical Research, Inc., New York
  • IMA Clinical Research, New York
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

  • Draig Clinical Site, New York
  • Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

  • Mount Sinai Hospital, New York
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

  • Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  • Adams Clinical Harlem, New York
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Cedarhurst
  • Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06963021

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  • Adams Clinical Harlem, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  • Integrative Clinical Trials, Brooklyn
  • Richmond Behavioral Associates, Staten Island
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 3, 2026 · NCT06775379

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  • Neurobehavioral Research, Inc., Cedarhurst
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  • Neurobehavioral Research, Inc, Cedarhurst
  • IMA Clinical Research - NYC Midtown, New York
  • IMA Clinical Research - NYC Uptown, New York
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Glen Oaks
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07196501

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Cedarhurst
  • Neurocrine Clinical Site, Mount Kisco
  • Neurocrine Clinical Site, New York
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

  • Clinical Research Site, Brooklyn
  • Clinical Research Site, New York
  • Clinical Research Site, New York
  • and 2 more
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217

Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

  • NYU Langone Health, New York
Recruiting
Ages 24 to 65 · All sexes · Updated Jun 29, 2026 · NCT07111390

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

  • Ima Clinical Research - Manhattan /ID# 278212, New York
  • Manhattan Behavioral Medicine /ID# 277910, New York
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997

tDCS: Sleep to Mood in Depression (S2M-D)

  • NYU Langone Health, New York
Recruiting
Ages 18 to 65 · All sexes · Updated Jun 8, 2026 · NCT07572526

Triage Survey for Psychiatry Research Eligibility

  • Adams Clinical, Harlem, New York
  • Adams Clinical, Bronx, The Bronx
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05800925

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  • The Medical Research Network, LLC, New York
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830

Aβ Dynamics in LLMD

  • NYU Langone Health, New York
  • Nathan S. Kline Institute for Psychiatric Research, Orangeburg
RecruitingPhase 4
Ages 60 and older · All sexes · Updated May 6, 2026 · NCT05004987

Mindfulness-Based fMRI Neurofeedback for Depression

  • Columbia University Irving Medical Center, New York
Recruiting
Ages 13 to 18 · All sexes · Updated Apr 29, 2026 · NCT05617495

Neutralizing Interleukin (IL)-6

  • Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Apr 29, 2026 · NCT07493317

Maintenance rTMS for Depression (Maitr-De)

  • Weill Cornell Medicine, New York
Recruiting
Ages 18 to 80 · All sexes · Updated Apr 29, 2026 · NCT06938841

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

  • Weill Cornell Medicine, New York
Recruiting
Ages 50 to 80 · All sexes · Updated Mar 27, 2026 · NCT05925322

Biomarker-guided rTMS for Treatment Resistant Depression

  • Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 22 to 65 · All sexes · Updated Feb 25, 2026 · NCT04041479

The Role of mGluR5 in CBT-I

  • Stony Brook University: Dept of Psychiatry, Stony Brook
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT07076342

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

  • NYU Langone Health, New York
  • Nathan Kline Institute for Psychiatric Research, Orangeburg
Recruiting
Ages 18 to 65 · All sexes · Updated Feb 5, 2026 · NCT05573074

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

  • Autobahn Site #105, Brooklyn
  • Autobahn Site #134, Brooklyn
  • Autobahn Site #104, Staten Island
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Mount Kisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.